Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Supportive care in severe and very severe aplastic anemia

Bone Marrow Transplantation volume 48, pages 168–173 (2013)Cite this article

Subjects

Abstract

Optimal management of aplastic anemia (AA) is not confined to immediate diagnosis, early decision making and timely initiation of major treatment strategies (immunosuppression or SCT) but also involves supportive treatment as a crucial part of patient care. Patients are threatened by complications of cytopenia. Here, we summarize current recommendations for prevention and early treatment of fungal, bacterial and viral infections, transfusion strategy and iron chelation and assess the evidence basis. In fact, many recommendations for patients with AA are not based on randomized studies in AA itself, but they are deduced from other conditions with similar severity of cytopenia. Prevention and treatment of complications like hemorrhage, bacterial and fungal infections and of secondary events like alloimmunization to blood products and iron overload have a significant impact on the prognosis of AA patients and need to be carefully observed in daily practice. More controlled studies on supportive care should be performed in this rare disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Passweg JR, Marsh JC . Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 36–42.

    Article  Google Scholar 

  2. Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ . Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis 2011; 52: 726–735.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430–438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117: 4434–4441.

    Article  CAS  PubMed  Google Scholar 

  5. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110: 1756–1761.

    Article  CAS  PubMed  Google Scholar 

  6. Valdez JM, Scheinberg P, Young NS, Walsh TJ . Infections in patients with aplastic anemia. Semin Hematol 2009; 46: 269–276.

    Article  PubMed  Google Scholar 

  7. Weinberger M, Elattar I, Marshall D, Steinberg SM, Redner RL, Young NS et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71: 24–43.

    Article  CAS  Google Scholar 

  8. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy–The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69–80.

    Article  CAS  PubMed  Google Scholar 

  9. Gafter-Gvili A, Ram R, Raanani P, Shpilberg O . Management of aplastic anemia: the role of systematic reviews and meta-analyses. Acta Haematol 2011; 125: 47–54.

    Article  PubMed  Google Scholar 

  10. Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L . Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane. Database. Syst Rev 2005; 19: CD004386.

    Google Scholar 

  11. Gafter-Gvili A, Fraser A, Paul M, Leibovici L . Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979–995.

    Article  PubMed  Google Scholar 

  12. Gafter-Gvili A, Paul M, Fraser A, Leibovici L . Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 5–22.

    Article  CAS  PubMed  Google Scholar 

  13. Gafter-Gvili A, Paul M, Fraser A, Leibovici L . Antibiotic prophylaxis in neutropenic patients. Isr. Med Assoc J 2007; 9: 460–462.

    CAS  Google Scholar 

  14. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107: 1743–1751.

    Article  CAS  PubMed  Google Scholar 

  15. Schlesinger A, Paul M, Gafter-Gvili A, Rubinovitch B, Leibovici L . Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 97–107.

    Article  PubMed  Google Scholar 

  16. van TF, Harbers MM, Terporten PH, van Boxtel RT, Kessels AG, Voss GB et al. Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: a study of safety. Ann Oncol 2007; 18: 1080–1084.

    Article  Google Scholar 

  17. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008; 26: 5684–5688.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Moody K, Finlay J, Mancuso C, Charlson M . Feasibility and safety of a pilot randomized trial of infection rate: neutropenic diet versus standard food safety guidelines. J Pediatr Hematol Oncol 2006; 28: 126–133.

    Article  PubMed  Google Scholar 

  19. DeMille D, Deming P, Lupinacci P, Jacobs LA . The effect of the neutropenic diet in the outpatient setting: a pilot study. Oncol Nurs Forum 2006; 33: 337–343.

    Article  PubMed  Google Scholar 

  20. Jubelirer SJ . The benefit of the neutropenic diet: fact or fiction? Oncologist 2011; 16: 704–707.

    Article  PubMed  PubMed Central  Google Scholar 

  21. U.S Department of Agriculture Food safety of people with cancer 2011 20-3-2012.

  22. Mattner F, Bange FC, Meyer E, Seifert H, Wichelhaus TA, Chaberny IF . Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the german society for hygiene and microbiology. Dtsch Arztebl Int 2012; 109: 39–45.

    PubMed  PubMed Central  Google Scholar 

  23. Gould D . Nurses' hand decontamination practice: results of a local study. J Hosp Infect 1994; 28: 15–30.

    Article  CAS  PubMed  Google Scholar 

  24. Hayes-Lattin B, Leis JF, Maziarz RT . Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant 2005; 36: 373–381.

    Article  CAS  PubMed  Google Scholar 

  25. Khan SA, Wingard JR . Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr 2001; 29: 31–36.

    Article  Google Scholar 

  26. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471–5489.

    Article  CAS  PubMed  Google Scholar 

  27. Wingard JR, Eldjerou L, Leather H . Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Curr Opin Hematol 2012; 19: 21–26.

    Article  CAS  PubMed  Google Scholar 

  28. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS . Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2012; 119: 345–354.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Marsh JC, Socie G, Schrezenmeier H, Tichelli A, Gluckman E, Ljungman P et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 1994; 344: 172–173.

    Article  CAS  PubMed  Google Scholar 

  31. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 2009; 94: 712–719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43–70.

    Article  CAS  PubMed  Google Scholar 

  33. Marsh JC, Ganser A, Stadler M . Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol 2007; 44: 138–147.

    Article  CAS  PubMed  Google Scholar 

  34. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002; 119: 1075–1082.

    Article  CAS  PubMed  Google Scholar 

  35. Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007; 109: 2794–2796.

    Article  CAS  PubMed  Google Scholar 

  36. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009–1013.

    CAS  PubMed  Google Scholar 

  37. Quillen K, Wong E, Scheinberg P, Young NS, Walsh TJ, Wu CO et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009; 94: 1661–1668.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ljungman P, Small TN . Vaccination of SCT recipients. Bone Marrow Transplant 2011; 46: 621.

    Article  CAS  PubMed  Google Scholar 

  39. Jeong SH, Lee HS . Hepatitis A: clinical manifestations and management. Intervirology 2010; 53: 15–19.

    Article  PubMed  Google Scholar 

  40. Viallard JF, Boiron JM, Parrens M, Moreau JF, Ranchin V, Reiffers J et al. Severe pancytopenia triggered by recombinant hepatitis B vaccine. Br J Haematol 2000; 110: 230–233.

    Article  CAS  PubMed  Google Scholar 

  41. Hendry CL, Sivakumaran M, Marsh JC, Gordon-Smith EC . Relapse of severe aplastic anaemia after influenza immunization. Br J Haematol 2002; 119: 283–284.

    Article  CAS  PubMed  Google Scholar 

  42. Bengtsson C, Kapetanovic MC, Kallberg H, Sverdrup B, Nordmark B, Klareskog L et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2010; 69: 1831–1833.

    Article  CAS  PubMed  Google Scholar 

  43. Salemi S, D'Amelio R . Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol 2010; 29: 270–314.

    Article  CAS  PubMed  Google Scholar 

  44. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606–613.

    CAS  PubMed  Google Scholar 

  45. Piccin A, O'Marcaigh A, Smith O, O'Riordan J, Crowley M, Vandenberg E et al. Outcome of bone marrow transplantation in acquired and inherited aplastic anaemia in the Republic of Ireland. Ir J Med Sci 2005; 174: 13–19.

    Article  CAS  PubMed  Google Scholar 

  46. Hernandez-Boluda JC, Marin P, Carreras E, Aguilar JL, Granena A, Rozman C et al. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience. Haematologica 1999; 84: 26–31.

    CAS  PubMed  Google Scholar 

  47. Killick SB, Win N, Marsh JC, Kaye T, Yandle A, Humphries C et al. Pilot study of HLA alloimmunization after transfusion with pre- storage leucodepleted blood products in aplastic anaemia. Br J Haematol 1997; 97: 677–684.

    Article  CAS  PubMed  Google Scholar 

  48. Desmarets M, Cadwell CM, Peterson KR, Neades R, Zimring JC . Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood 2009; 114: 2315–2322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861–1869.

  50. Dzik WH . Leukoreduction of blood components.. Curr Opin Hematol 2002; 9: 521–526.

    Article  PubMed  Google Scholar 

  51. The 2009 Annual Short Report (2010). Taylor, C, Cohen, H, Mold, D, Jones, HobotSHoTSSG (eds.). 2010.

  52. Kaminski ER, Hows JM, Goldman JM, Batchelor JR . Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens. Br J Haematol 1990; 76: 401–405.

    Article  CAS  PubMed  Google Scholar 

  53. German Association of Physicians. Cross-sectional guidelines for therapy with blood components and plasma derivatives. Transfus Med Hemother 2009; 36: 347–481.

    Article  Google Scholar 

  54. Sagmeister M, Oec L, Gmur J . A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93: 3124–3126.

    CAS  PubMed  Google Scholar 

  55. Höchsmann B, Seidel H, Wiesneth M, Schrezenmeier H . Is the low platelet transfusion trigger in the new cross-sectional German guidelines of risk in outpatient setting? Prophylactic platelet transfusions in aplastic anemia. Transfus Med Hemother 2010; 36: 38.

    Google Scholar 

  56. Schrezenmeier H, Seifried E . Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99: 1–15.

    Article  CAS  PubMed  Google Scholar 

  57. Laundy GJ, Bradley BA, Rees BM, Younie M, Hows JM . Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion 2004; 44: 814–825.

    Article  CAS  PubMed  Google Scholar 

  58. Bean MA, Graham T, Appelbaum FR, Deeg HJ, Schuening F, Sale GE et al. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. Transplantation 1994; 57: 423–426.

    Article  CAS  PubMed  Google Scholar 

  59. Marsh J, Socie G, Tichelli A, Schrezenmeier H, Hochsmann B, Risitano AM et al. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br J Haematol 2010; 150: 377–379.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Fast LD, DiLeone G, Marschner S . Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51: 1397–1404.

    Article  CAS  PubMed  Google Scholar 

  61. Vamvakas EC . Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005; 19: 181–199.

    Article  PubMed  Google Scholar 

  62. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD . Use of leukocyte-depleted platelets and cytomegalovirus- seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246–250.

    CAS  PubMed  Google Scholar 

  63. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments]. Blood 1995; 86: 3598–3603.

    CAS  PubMed  Google Scholar 

  64. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M . Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195–4200.

    Article  CAS  PubMed  Google Scholar 

  65. Paphilon DH, Rider JR, Barbara JA, Williamson LM . Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med 1999; 9: 115–123.

    Article  Google Scholar 

  66. Lee JW . Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea. Int J Hematol 2008; 88: 16–23.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Kim KH, Kim JW, Rhee JY, Kim MK, Kim BS, Kim I et al. Cost analysis of iron-related complications in a single institute. Korean J Intern Med 2009; 24: 33–36.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Kushner JP, Porter JP, Olivieri NF . Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001; 1: 47–61.

    Article  Google Scholar 

  69. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487–494.

    Article  CAS  PubMed  Google Scholar 

  70. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799–805.

    Article  CAS  PubMed  Google Scholar 

  72. Koreth J, Antin JH . Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica 2010; 95: 364–366.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Deeg HJ, Spaulding E, Shulman HM . Iron overload, hematopoietic cell transplantation, and graft-versus-host disease. Leuk Lymphoma 2009; 50: 1566–1572.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Gattermann N . Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007; 31 (Suppl 3): S10–S15.

    Article  CAS  PubMed  Google Scholar 

  75. Gattermann N . Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008; 88: 24–29.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Neufeld EJ . Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107: 3436–3441.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Park SJ, Han CW . Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008; 23: 320–323.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Mwanda OW, Otieno CF, Abdalla FK . Transfusion haemosiderosis inspite of regular use of desferrioxamine: case report. East Afr Med J 2004; 81: 326–328.

    CAS  PubMed  Google Scholar 

  79. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M et alTailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557–566.

  80. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010; 116: 2448–2454.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Clinical Transfusion Medicine, German Red Cross Blood Transfusion Service, Baden-Württemberg—Hessia and University of Ulm, Ulm, Germany

    B Höchsmann & H Schrezenmeier

  2. Second Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania

    A Moicean

  3. Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy

    A Risitano

  4. Department of Hematology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden,

    P Ljungman

Authors
  1. B Höchsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Moicean
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Risitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Ljungman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Schrezenmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the EBMT Working Party on Aplastic Anemia

Corresponding author

Correspondence to H Schrezenmeier.

Ethics declarations

Competing interests

The authors declare no conflict of interest

Rights and permissions

Reprints and permissions

About this article

Cite this article

Höchsmann, B., Moicean, A., Risitano, A. et al. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant 48, 168–173 (2013). https://doi.org/10.1038/bmt.2012.220

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.220

Keywords

This article is cited by

Search

Advanced search

Quick links